📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Fischer Medical Ventures Subsidiary Acquires 75% Stake in Indonesian Medical Firm
Fischer Medical Ventures Limited's wholly owned subsidiary, FMV Global Innovations Pte Limited, has acquired a 75% stake in PT Fischer Pariko Medical Ventures. The target entity is a newly incorporated Indonesian company focused on the wholesale of medical, scientific, and precision equipment. As the entity was incorporated in October 2024, it reported nil turnover for the 2024-25 period. This acquisition marks a strategic expansion for Fischer Medical into the Southeast Asian healthcare market.
Key Highlights
Acquisition of 75% stake in PT Fischer Pariko Medical Ventures via a 100% owned subsidiary.
Target entity is based in Indonesia and operates in the healthcare and medical equipment wholesale industry.
The acquired company is a startup incorporated on October 14, 2024, with nil revenue for FY24-25.
The move signifies an international expansion strategy into the Indonesian medical equipment market.
💼 Action for Investors
Investors should monitor the operational progress of this new Indonesian venture as it begins generating revenue. While the acquisition is strategic, the target is a startup, so immediate financial impact will be limited.
Fischer Medical Launches India's First Helium-Free 1.5T MRI Platforms MICA and QUIN
Fischer Medical Ventures Limited, through its subsidiary Time Medical India, has launched two advanced 1.5T MRI platforms, MICA and QUIN, at IRIA 2026. QUIN is distinguished as India's first helium-free 1.5T wide 70 cm bore MRI system, which eliminates helium dependency and simplifies installation. Both systems have secured CDSCO certification, allowing for immediate commercial rollout in the Indian healthcare market. These launches represent a significant technological milestone for the company in the sustainable medical imaging sector.
Key Highlights
Launched QUIN, India's first helium-free 1.5T wide 70 cm bore MRI system.
Introduced MICA, a 1.5T 32-channel MRI with 1000-litre zero boil-off magnet technology.
Both MRI platforms have received mandatory CDSCO certification for the Indian market.
QUIN features a no-quench-pipe auto ramp unit, reducing infrastructure requirements.
Systems are available in 32 and 64-channel configurations for high-resolution imaging.
💼 Action for Investors
The launch of India's first helium-free MRI technology positions Fischer as a leader in cost-effective medical imaging. Investors should watch for order book growth and hospital partnerships following this launch.
Fischer Medical Subsidiary Secures Rs 40 Crore Loan from HDFC Bank
Fischer Medical Ventures' material subsidiary, Time Medical International Ventures (India) Private Limited, has entered into a secured loan agreement with HDFC Bank for Rs 40 Crores. The loan carries an interest rate of 3 months Repo plus 2.75% per annum. The facility is secured by a pledge of shares and Fixed Deposit collateral. This capital infusion will likely support the subsidiary's operational requirements or growth initiatives.
Key Highlights
Loan amount of Rs 40 Crores sanctioned by HDFC Bank to the material subsidiary.
Interest rate set at 3 months Repo rate + 2.75% per annum.
Loan is secured through pledged shares and Fixed Deposit (FD) collateral.
Agreement approved by the Board of Directors on January 30, 2025.
💼 Action for Investors
Investors should monitor the utilization of these funds and the subsequent impact on the subsidiary's revenue growth. The debt addition is manageable given the secured nature and competitive interest pricing.
Fischer Medical Q3 FY26 Consolidated Revenue Surges to ₹101 Cr; PAT at ₹19.2 Cr
Fischer Medical Ventures reported a massive jump in consolidated revenue to ₹10,109.52 Lakhs for Q3 FY26, compared to ₹1,174.85 Lakhs in the same quarter last year. The company turned profitable on a consolidated basis with a PAT of ₹1,923.48 Lakhs, a significant recovery from a loss of ₹29.39 Lakhs in Q3 FY25. For the nine-month period, consolidated revenue reached ₹21,084.52 Lakhs, marking a substantial growth over the previous year's ₹6,152.45 Lakhs. However, the standalone business reported a loss of ₹166.93 Lakhs for the quarter, indicating that growth is heavily driven by its subsidiaries.
Key Highlights
Consolidated revenue grew by approximately 760% YoY to ₹10,109.52 Lakhs in Q3 FY26.
Consolidated PAT turned positive at ₹1,923.48 Lakhs versus a loss of ₹29.39 Lakhs in the previous year's quarter.
Nine-month consolidated PAT stands at ₹3,813.89 Lakhs compared to a loss of ₹10.42 Lakhs in the prior period.
Board approved restructuring of Malaysian subsidiary Fischer Hospitality Sdn. Bhd. with a trustee holding 51%.
Company Secretary and Compliance Officer Mr. Aravindkumar V resigned effective February 10, 2026.
💼 Action for Investors
The massive consolidated growth and turnaround to profitability are strong positive signals, though investors should note that the standalone entity remains in a loss. Monitor the appointment of the new Compliance Officer and the progress of the Malaysian subsidiary restructuring.
Fischer Medical Ventures enters Indonesia for TB Eradication
Fischer Medical Ventures Limited, through its subsidiary Time Medical International Ventures (India) Pvt Ltd, is entering Indonesia via a TB eradication partnership with the City of Jember. This collaboration involves PT Pariko and includes a pilot deployment of 250 AI-powered X-ray systems by March 2026. The order size is approximately USD 6.5 million, positioning FMV as a strategic partner in Indonesia’s public healthcare initiatives. This expansion could positively impact the company's revenue stream in the coming years.
Key Highlights
Time Medical International Ventures (India) Pvt Ltd enters Indonesia
Pilot deployment of 250 units of AI-powered X-ray systems planned by March 2026
Order size is approximately USD 6.5 million
Partnership with the City of Jember for TB eradication
💼 Action for Investors
Investors should monitor the progress of the pilot deployment and the potential for further expansion in Indonesia. Keep an eye on revenue growth related to this international venture.